All In MedTech

Device Trial Radar · NCT05866419

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and DElivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar PunctuRE Trial (PIERRE)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 27, 2023

Primary completion

Apr 2028

Study completion Jul 2030

Sponsor

Lead sponsor
Alcyone Therapeutics, IncNot on our public-company list
Sponsor type
Industry
Collaborators
Biogen
First posted
May 19, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.

Conditions

  • Spinal Muscular Atrophy
  • Spine Deformity
  • Scoliosis

Interventions

  • ThecaFlex DRx SystemDevice

    The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and CatheterTime frame: 12 Months
  2. The proportion of subjects with successful Intrathecal Therapy Infusion(s) through 12 monthsTime frame: 12 Months

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona · Recruiting

  • Children's Hospital Orange County

    Orange, California · Recruiting

  • Stanford Medical Center

    Palo Alto, California · Recruiting

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.